What is Immunai?
Founded in 2018 and headquartered in New York City, Immunai operates at the vanguard of precision medicine. The company has developed a sophisticated AI platform capable of analyzing the human immune system with unprecedented granularity. By integrating single-cell genomics with machine learning, Immunai provides pharmaceutical and biotech partners with actionable insights into immune cell behavior. This technological capability is essential for identifying novel drug targets and optimizing clinical trial designs, effectively reducing the time and cost associated with bringing life-saving therapies to market. As a leader in the digital health sector, Immunai is redefining how researchers interpret biological data to address unmet medical needs.
How much funding has Immunai raised?
Immunai has raised a total of $295M across 3 funding rounds:
Angel/Seed
$20M
Series A
$60M
Series B
$215M
Angel/Seed (2020): $20M with participation from TLV Partners and Viola Group
Series A (2021): $60M, investors not publicly disclosed
Series B (2021): $215M supported by Talos, 8VC, Koch Disruptive Technologies, and Alexandria Venture Investments
Key Investors in Immunai
TLV Partners
TLV Partners is an Israeli venture capital firm that invests in early-stage startups, collaborating with innovative entrepreneurs to create category-defining companies. With over $1 billion under management, the firm focuses on exceptional teams that are poised to shape the future across various sectors, including AI, healthcare, and application security.
Viola Group
Viola Group is Israel's leading technology investment group, managing over $6 billion in assets. The firm supports Israeli entrepreneurs in building transformational technology companies through its multi-strategy investment approach, catering to companies at various stages of development.
Alexandria Venture Investments
Alexandria Venture Investments is the strategic venture capital arm of Alexandria Real Estate Equities, focusing on innovative life science and healthcare companies. They provide critical capital and industry expertise to startups developing breakthrough technologies in the biopharmaceutical and medical device sectors.
What's next for Immunai?
With the recent influx of capital, Immunai is well-positioned to scale its operations and expand its research capabilities. The strategic focus will likely center on deepening its data repository and enhancing the predictive accuracy of its AI models. By fostering partnerships with global pharmaceutical leaders, the company aims to solidify its role as an indispensable infrastructure provider for the next generation of immunotherapy development. Future growth will be driven by the continued refinement of its computational engine, enabling more precise patient stratification and the identification of biomarkers that could revolutionize personalized medicine. As the company matures, its ability to translate complex immunological data into clinical success will remain the primary metric for its long-term valuation and industry influence.
See full Immunai company page
